Platform

ALiCE, a novel T cell redirecting bi-specific antibody

T cell redirecting bispecific antibodies have shown effective redirection of T cells onto tumor cells and thereby specifically kill the tumor cells, in turn, leads to very potent and long-lasting efficacy in the treatment of cancer patients. Nevertheless, excessive toxicity and low developability have been the main limitations in most of currently available technologies. Our new platform technology ALiCE has strong potential to address these unmet needs by utilizing unique 2-by-1 structure and innate cellular assembly mechanism.

ALiCE : Antibody Like Cell EngagerNovel bispecific Antibody Platform Technology
A proprietary bi-specific antibody platform with unique two by one structure to minimize the toxicity.
ALiCE preserves the F(ab’)2 structure of the parental antibody to maintain high binding affinity to the cancer antigen and substitutes the Fc region with a monovalent Fv to induce immune response.

ALiCE Points of Differentiation

Safety(Minimizing Off-target Cytotoxicity)
Modulating avidity of respective binding arms. ALiCE binds to tumor cells with two binding arms and recruit effector cells with only one binding arm. The two-by-one structure resulting in higher avidity for tumor cells to minimize off-target toxicity.

 

Immunogenicity(Bispecific Antibody Without Mutated Structure)
Unlike other bispecific antibodies with mutated structures or linkers, ALiCE enables to create bispecific antibodies composed of only natural elements.

 

Easy to Make(Utilizing innate assembly mechanism of Cell Lines)
In contrast to mutation-based engineering, ALiCE harnesses a natural assembly mechanism in cell lines, elegantly utilizing the innate affinity of VH-VL to form heterodimerization of the heavy chain.

Publication Download